The Pink Sheet article described comment letters to HHS’ drug pricing blueprint recommending that cost-effectiveness analyses by ICER could help promote value-based pricing in government-sponsored insurance. While IVI concurs value assessment is noble, worthwhile and needed, IVI cautions about making centralized pricing decisions based on centralized value assessments within the U.S.’s current decentralized health care system. We encourage a community-network approach to value assessment that is fully transparent, better incorporates patients’ perspectives and is flexible for multiple users, including purchasers, payer, providers and patients.

Read the full article here. (Note: Pink Sheet subscription required.)